Amoy Diagnostics Co., Ltd.
艾德生物
300685
Shenzhen Stock Exchange
Company Profile
The company’s major advantages are solid R&D base, distribution channel, brand image and innovative products. Since founded, the Company has attached great importance to R&D and technological innovation; setting up dual R&D centers in Xiamen and Shanghai, being clinical and patient centric, being down-to-earth and taking the initiatives to build strictly compliant PCR, NGS, FISH, IHC platforms for precision medicine, the Company's annual R&D investment accounts for more than 15% of the revenue. Over ten years’ steady growth in R&D investment and intensive R&D development, the globally leading and fully independent intellectual property rights of technologies, ADx-ARMS®, Super-ARMS®, ddCapture®, ADx-HANDLE®, as well as ADx-GSS® technologies, has laid a technical foundation for its sustainable development. Based on the advantages of these core technologies, the Company offers a wide portfolio of detection assays covering multiple cancer types, most of which are first-in-class and unique in China and NMPA approved, some are CE-marked in Europe, some are registered in Japan and South Korea and included on its National Health Insurance List. The company has established a strong compound R&D team with high technical level and rich industry experience. It has participated in a number of national, provincial and ministerial-level projects such as the 863 Program, the National Science and Technology Major Project, and the Health Industry Scientific Research Project. The Company has been qualified as National Center of Enterprise Technology, Postdoctoral Programme, and etc. On the basis of technology and product advantages, the Company has a sound marketing structure. Domestic market: direct sales network covering top hospitals, the sales team consists of more than 400 people, a complete pre-sales and after-sales team provides marketing, medical and technical supports activities; moreover, the Company actively expand cooperation with pharmaceutical companies. In the international market: the Company has more than 70 full-time employees are responsible for international business and business development. The Company has wholly-owned subsidiaries in Singapore, Hong Kong, and Canada, and one European warehouse in the Netherlands. It cooperates closely with oncologists, customers, and pharmaceutical companies to continuously promote local registrations and marketing. At the same time, the Company's products participate in the clinical trials of the original research drugs of many pharmaceutical companies in the form of companion diagnostics, and make every effort to develop the international market. The Company is a partner of multinational pharmaceutical companies including AstraZeneca, Johnson & Johnson, Amgen, Eli Lilly, Merck, Pfizer, etc. It has won a good market reputation and extensive customer recognition, and has become an internationally renowned Chinese brand.
Full description
Since founded, Amoy Diagnostics (the Company) has been devoted to research and develop molecular diagnostics assays for precision oncology, focus on technology innovations that are state-of-the-art and regulatory compliance, which altogether ensure cancer patients benefit from the high quality testing reagents and service. After years of technology accumulation and sales channel construction, a product line with advanced technology and complete varieties has been strengthened; meanwhile, a strong and competent team of R&D and sales talents has been established. The Company’s main business is research and develop, produce and sell molecular diagnostic products for oncology precision medicine, and according testing services. The Company has been qualified as National Center of Enterprise Technology, Postdoctoral Programme, and etc. The GMP standard manufacturing building is NMPA and ISO13485 accredited. The globally leading and fully independent intellectual property rights of technologies, ADx-ARMS®, Super-ARMS®, ddCapture®, ADx-HANDLE®, as well as ADx-GSS® technologies, were granted patents in China, the US, EU and Japan. Based on the advantages of these core technologies, the Company offers a wide portfolio of detection assays covering multiple cancer types, most of which are first-in-class in China and NMPA approved, some are CE-marked in Europe, some are registered in Japan and South Korea and included on its National Health Insurance List. Additionally, the company established two central labs in Xiamen and Shanghai. They are CAP accredited, and fully qualified for providing clinical testing services to pharmaceutical companies and cancer patients in China. Aiming at the source of industry innovation and empowering the clinical trial of original drugs with companion diagnostics, the Company has built up strategic partnerships with top domestic and international pharmaceutical companies such as AstraZeneca, Johnson & Johnson, Amgen, Eli Lilly, Merck, Hengrui, and BeiGene. The Company’s products have been sold to hundreds of large and medium-sized hospitals and research institutes in more than 60 countries and regions around the world, help over 600,000 patients every year around the world to benefit from precision medicines.